长效生长抑素类似物对神经内分泌肿瘤患者68Ga-DOTATATE摄取影响的前瞻性观察研究
该前瞻性观察研究纳入296例神经内分泌肿瘤患者,评估长效生长抑素类似物对68Ga-DOTATATE PET/CT摄取的影响。结果显示治疗开始后正常肝脏SUVmax显著降低,而肿瘤病灶SUVmax无显著变化,且停药间隔对SUVmax无显著影响。
要点
- 长效生长抑素类似物治疗开始后正常肝脏SUVmax显著降低。
- 肿瘤病灶SUVmax在治疗前后无显著变化。
- 停药间隔对正常肝脏或肿瘤病灶SUVmax无显著影响。
核心结论
- 长效生长抑素类似物治疗不改变肿瘤病灶SUVmax,但正常肝脏SUVmax在治疗后显著降低。
研究设计与样本
- 2013至2016年前瞻性观察研究,纳入296例确诊或疑似神经内分泌肿瘤患者。
- 主要分析两组人群:治疗前及治疗后至少一次PET/CT者,以及持续治疗者中分析停药间隔影响。
- 探索性分析评估临床疾病进展、消退或稳定对68Ga-DOTATATE摄取的影响。
主要发现
- 正常肝脏中位SUVmax治疗前为8.6(四分位距7.4-10.2),治疗后为6.0(4.7-8.0),P<0.001。
- 肿瘤病灶SUVmax治疗开始后无显著变化。
- 正常肝脏或肿瘤病灶SUVmax与末次长效生长抑素类似物剂量至PET/CT间隔无显著差异。
关键数值与推荐
- 指南推荐末次长效生长抑素类似物剂量与显像之间间隔3-4周。
临床怎么用
- 解读68Ga-DOTATATE PET/CT用于生长抑素类似物治疗后疗效评估时需考虑正常肝脏SUVmax降低。
- 研究结果对PET/CT前停用生长抑素类似物的指南有启示意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with neuroendocrine tumors (NETs) are often treated with somatostatin analogs (SSAs) for control of symptoms and tumor growth. Such therapy could theoretically lead to misinterpretation of somatostatin receptor imaging with 68Ga-DOTATATE PET/CT by interfering with tracer-receptor binding. Guidelines recommend an interval of 3-4 wk between the last dose and imaging. The aim of this study was to evaluate if long-acting (LA) SSA treatment changes the uptake of 68Ga-DOTATATE in patients with NETs. Methods: From 2013 to 2016, 296 patients with, or under evaluation for, NETs were included in this prospective observational study. The effect of LA SSA on tracer uptake was evaluated in 2 main patient populations: those undergoing 68Ga-DOTATATE PET/CT before starting LA SSA treatment and at least once afterward, and those receiving ongoing LA SSA therapy, in whom the effect of the interval between the last dose of LA SSA and the PET/CT exam was analyzed. A third, explorative, analysis was performed to evaluate if clinical disease progression, regression, or stable tumor status changed the uptake of 68Ga-DOTATATE. In the 3 analyses, measurements of SUVmax in normal liver and tumor lesions were compared. Results: The median SUVmax in normal liver was significantly higher before treatment (8.6; interquartile range, 7.4-10.2) than after treatment initiation (6.0; 4.7-8.0) (P < 0.001). No significant changes in SUVmax were seen in tumor lesions after treatment initiation. No significant differences in SUVmax were found in normal liver or tumor lesions dependent on the interval between last dose of LA SSA and PET/CT. Conclusion: Treatment with LA SSA does not change SUVmax in tumor lesions, whereas SUVmax in normal liver is significantly lower after treatment. The findings have implications for interpretation of 68Ga-DOTATATE PET/CT for response assessment after SSA therapy and for guidelines on discontinuation of treatment before PET/CT.
引用
- Gålne A, Almquist H, Almquist M, et al. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors. J Nucl Med. 2019. PMID: 31000584. doi:10.2967/jnumed.119.226332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。